

Jonas Heilskov Graversen  
Cancer- og Inflammationsforskning  
ATLAS - Center for Functional Genomics and Tissue Plasticity  
**Postadresse:**  
J.B. Winsløvs Vej 25, 2.  
5000  
Odense C  
Danmark  
**E-mail:** jgraversen@health.sdu.dk  
**Mobil:** 21733311  
**Telefon:** 65507275

## **Ansættelse på SDU**

### **Lektor**

Cancer- og Inflammationsforskning  
Syddansk Universitet  
Odense C  
1. dec. 2016 → present

### **Lektor**

ATLAS - Center for Functional Genomics and Tissue Plasticity  
Syddansk Universitet  
Odense M  
1. okt. 2017 → 30. sep. 2023

### **Bedømmer**

Helse Sør-Øst RHF  
Norge  
1. jan. 2018 → 31. dec. 2019

### **Medlem af bedømmelsespanelet for InnoBoosters grants**

Innovationsfonden  
1. jan. 2018 → 9. maj 2019

## **Ansættelse uden for SDU**

Dec-2011-present Chief Executive Officer, Affinicon ApS/Cytoguide ApS.

Sep-2016-Dec-2016 Project Director, CMC Biologics A/S

Aug-2007-Dec 2011 Chief Scientific Officer, Cytoguide ApS.

Jul-2006-Aug-2007 Senior Scientist, Symphogen A/S, Antibody Expression and Characterization.

Nov-2004-Jul-2006 Research Scientist, Novo Nordisk A/S, Diabetes Protein Engineering.

Jan-2004-Nov-2004 Senior Scientist, Borean Pharma A/S.

Apr-2000-Jan-2004 Research Manager and post doc, ProteoPharma ApS and Department of Medical Biochemistry, Aarhus University.

## **Education:**

- HD(O): Diploma degree in business administration; organization and management, 2015, Aarhus University
- PhD in Molecular Biology, 2000, at the Department of Molecular and Structural Biology, Aarhus University
- Master of Science, Chemistry-Biotechnology, 1997, Aarhus University

## **Education not part of MSc., PhD or HD(O)**

I have followed several courses at Danish University of Pharmacy offered as part of a Master in Industrial Drug Development (MIND) covering challenges met within drug development from target identification over safety pharmacology and CMC to clinical development and regulatory affairs.

- Patent Legislation (5 ECTS), 2009, Science and Technology, Aarhus University
- Chemical Process Development and Production of Active Pharmaceutical Ingredients (API) (3 ETCS), 2008, University of Copenhagen
- Non-clinical Safety and Toxicology (2.5 ETCS), 2007, Danish University of Pharmaceutical Sciences
- Drug Regulatory Affairs in Drug Development (2.5 ETCS), 2007, Danish University of Pharmaceutical Sciences
- QA, QC, GXP for Pharmaceutical Production (2.5 ECTS), 2006, Danish University of Pharmaceutical Sciences
- Drug Delivery (4 ECTS), 2006, Danish University of Pharmaceutical Sciences
- Target Identification and validation (2.5 ETCS), 2006, Danish University of Pharmaceutical Sciences
- Drug design and discovery (4 ECTS), 2006, Danish University of Pharmaceutical Sciences
- Project Management – Overview & Tools, 2006, Novo Nordisk internal course
- Discovery and development of Medicines (5 ECTS), 2006, Danish University of Pharmaceutical Sciences
- Pharmacology (2.5 ECTS), 2005, Danish University of Pharmaceutical Sciences
- Formulation development and drug delivery systems for therapeutic drugs, Chicago, 2005, American Chemical Society Continued Education course

### **Miscellaneous activities:**

- Member of advisory board for the Innobooster grants from Innovation Fund Denmark
- Member of scientific evaluation committee for Biomedical Research with a Translational Perspective, Helse Sør-Øst, Norway.
- September 2015, co-founder of Aimvion A/S an Aarhus University spin-off company
- Consultant for Aimvion A/S: (pre)clinical development plan and business development
- 2014-2015, advisor for the biotech start-up Buildthx ApS – a company developing IP from DTU
- August 2013, co-founder Affinicon ApS
- September 2007, co-founder of Cytoguide ApS
- Has worked as consultant for Capnova A/S, a state owned venture company
- May 2006 the ProteoPharma portfolio of patents sold to F. Hoffmann-La Roche Ltd
- January 2004, ProteoPharma ApS is sold to Borean Pharma A/S
- January 2000, co-founder of ProteoPharma ApS
- During PhD study co-inventor of two patents that eventually formed part of the intellectual property of the company Borean Pharma A/S. Patents later sold to Anaphore Inc (La Jolla, Ca)
- Member of the Industry Advisory Board for the Molecular Medicine education at Health, Aarhus University and of censor team for Danish biotechnology-engineer educations

### **Summary:**

Skilled protein chemist and engineer with a strong entrepreneurial drive and a keen eye for innovation and strategic options. Especially experienced in discovery, translational research and planning transition into early development phase, balancing stakeholders from business and academia and finding mutual goals. Co-founder of four biotech companies, one exit accomplished (35 mill. €), sale to Roche Pharma GmbH.

I have several years' experience in managing projects, both within academia and in biotech, and have acted as daily manager of scientific teams in both academia and industry. I have been responsible for interactions with external partners, and investors and for patenting strategy. Further, I have been involved in interactions with CMOs and CROS as a user, as well as Project Director at a CMO.

More than 45 patents and publications. ORCID: 0000-0001-7119-2108, Web of Science: cites=1868, h-index=17, Google scholar: cites 2,705.